a guidance for companies to evaluate their internal control adequacy. This evaluation form is based on COSO1s framework (The Committee of Sponsoring Organizations of the Treadway Commission) revised
, medical device business is expected to be growth at an average rate of 8.5-10.0% per year. This growth will be supported by: (i) government policy, focused on promoting investment in the sector through the
1,921 million decreased by 7% compared to the previous year. It derived from: • Revenues from sales and services of medical device business for the year 2019 were Baht 1,798 million decreased by 3% in
% -2.4% Prepaid 113 92 86 -24% -6.5% Blended 138 118 112 -19% -5.1% VOU (GB/data sub/month) Postpaid 14.4 16.6 17.0 18% 2.3% Prepaid 10.3 11.1 13.8 34% 23% Blended 11.4 12.7 14.7 29% 16% Device Penetration
appropriate by Dhipaya Bodin as a joint venture. It will benefit potential shareholders in the medical device and distribution business. The current production and distribution line is Blood Line with a
anytime, anywhere, with any device. Meanwhile, data used by consumers which has been detected and compiled in the digital format is regarded as a business asset which can be further processed and analyzed
-brand portfolio strategy to maintain Q1’19 market share in energy drinks at 53.7%, which aligned with our mid-term guidance. In functional drinks market, C-Vitt maintained its leadership position, with
Company has not yet been able to provide guidance for our 2020 full year results. The Company has modelled the impact of downside scenarios for the business at various severity levels, and implemented
Principles on Client Identification And Beneficial Ownership For The Securities Industry และ Anti-Money Laundering Guidance for Collective Investment Schemes จึงขอเปิดโอกาสให้บริษัทหลักทรัพย์และผู้ประกอบธุรกิจ